# A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before

Study · id `cardio:ct-nct04460885` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04460885](<https://clinicaltrials.gov/study/NCT04460885>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT04460885

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 984 participants.

## Technical summary

Registry record NCT04460885. Randomized; no masking; primary purpose treatment. Start 2020-11-25 (actual); primary completion 2022-05-29 (actual). Results posted on 2025-06-12.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 984 participants (enrolled count; ClinicalTrials.gov record NCT04460885, source copy `cardio:ctgov-nct04460885-2025-12-04`, retrieved 2026-11-18)
- Started: 2020-11-25 (actual) (ClinicalTrials.gov record NCT04460885, source copy `cardio:ctgov-nct04460885-2025-12-04`, retrieved 2026-11-18)
- Primary completion: 2022-05-29 (actual) (ClinicalTrials.gov record NCT04460885, source copy `cardio:ctgov-nct04460885-2025-12-04`, retrieved 2026-11-18)
- Completion: 2022-12-01 (actual) (ClinicalTrials.gov record NCT04460885, source copy `cardio:ctgov-nct04460885-2025-12-04`, retrieved 2026-11-18)
- Results first posted: 2025-06-12 (ClinicalTrials.gov record NCT04460885, source copy `cardio:ctgov-nct04460885-2025-12-04`, retrieved 2026-11-18)
- Countries: United States; Croatia; India; Israel; Italy; Japan; Mexico; Poland; Puerto Rico; Russia; Slovakia; Spain; United Kingdom (ClinicalTrials.gov record NCT04460885, source copy `cardio:ctgov-nct04460885-2025-12-04`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04460885-2025-12-04`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before
- Acronym: ONWARDS 1
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Insulin icodec
- Intervention (Drug): Insulin glargine
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin (`cardio:pubmed-37356066`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Continuous glucose monitoring-based metrics and the duration of hypoglycaemia events with once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-naive type 2 diabetes: an exploratory analysis of ONWARDS 1 (`cardio:pubmed-39374601`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a6dc0a0641ea1dbd9e5db2164fefab82d12b2983a6ddb7079d39e82e9c1f698e
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
